A Neurobiological Model of Anhedonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-19

Study Completion Date

2024-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to better understand anhedonia in Major Depressive Disorder by investigating the reward-related neural and inflammatory correlates.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dopamine Neurotransmission in Major Depression

NCT01659814

Major Depressive Disorder Anhedonia

COMPLETED

Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients

NCT05383248

Anhedonia Depression

COMPLETED NA

A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

NCT03148522

Diagnosis and Treatment of Depression

UNKNOWN NA

Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment

NCT02859103

Depression Anhedonia

COMPLETED PHASE4

Behavioral Processes Underlying Reward Processing in Depression

NCT00205933

Major Depressive Disorder Bipolar Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Despite extensive research on the treatment of Major Depressive Disorder (MDD) relapse rates are as high as 80%. Of those, 30-40% fall into the severe spectrum called treatment resistant depression (TRD) as they fail to respond to at least two lines of antidepressant treatment interventions. TRD has been linked with anhedonia, the inability to experience pleasure or interest in usually enjoyable activities. The neurobiology of anhedonia is poorly understood with recent literature examining an inflammatory association and linking it to deficits in reward-related brain circuitry. The present study examines neurobiological correlates of anhedonia in MDD and TRD, specifically C-Reactive Protein (CRP), IL-6 and ventral striatal (VS) activity. The study also explores whether VS activity mediates the association between inflammation and anhedonia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anhedonia Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Major Depressive Disorder including TRD

Treatment resistant depression (TRD) participants are defined as participants with Major Depressive Disorder (MDD) who fail to respond to at least two lines of antidepressant medication treatment interventions.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current diagnosis of MDD based on the MINI International Neuropsychiatric Interview (MINI)
* For treatment resistant depression participants: unsuccessful treatment with at least 2 types or doses of antidepressant medication treatment
* Right-handed
* Capacity for informed consent
* Score a 9 or higher on the MADRS

Exclusion Criteria

* Comorbid Bipolar Disorder
* Substance use disorder in the last 12 months
* Schizophrenia, and other psychotic disorders
* Comorbid illness such as endocrinological illness (e.g. Cushing's disease) rheumatologic illness (e.g., systemic Lupus erythematosus, current treatment with glucocorticoids), and autoimmune diseases (e.g. psoriasis)
* Pregnancy
* Daily NSAID or aspirin use and any metallic implant
* Visual/Hearing Impairments that would keep participant from being able to complete tasks

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes